The other day, we hosted an hourlong webinar on how to analyze clinical trials to best spot red flags before they cause trouble. The response was terrific and we thank you for your interest.
But because we only had a limited time for the webinar, we weren’t able to address all of your questions. We have collected some more and compiled the responses below.
What conditions compel single-arm trials, given it is not the best mode of testing a drug?
Clear and concise answers to some great additional questions.
Will be reading those SECs even more diligently.
Just wondering what percentage of phase 2/3 trials for new
anti-cancer treatments are single arm?
If you need expert statisticians to give a meaning to your clinical trials, it means the drug is either not working, or it is not worth